{"id":23931,"date":"2024-03-05T12:38:14","date_gmt":"2024-03-05T20:38:14","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/"},"modified":"2026-03-19T14:58:09","modified_gmt":"2026-03-19T21:58:09","slug":"ultomiris-a-treatment-for-generalized-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/","title":{"rendered":"Ultomiris: Un tratamiento para la miastenia grave generalizada"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Si le diagnostican una enfermedad generalizada <a href=\"https:\/\/ameripharmaspecialty.com\/es\/myasthenia-gravis\/myasthenia-gravis\/\">miastenia gravis<\/a> (gMG), su proveedor de atenci\u00f3n m\u00e9dica podr\u00eda recetarle Ultomiris.&nbsp;<\/span><\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#What_Is_Ultomiris\" >\u00bfQu\u00e9 es Ultomiris?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#What_Happens_in_Generalized_Myasthenia_Gravis\" >\u00bfQu\u00e9 ocurre en la miastenia grave generalizada?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#How_Does_Ultomiris_Work\" >\u00bfC\u00f3mo funciona Ultomiris?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#Ultomiris_Mode_of_Action\" >Modo de acci\u00f3n del Ultomiris<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#How_Is_Ultomiris_Administered_to_Myasthenia_Gravis_Patients\" >\u00bfC\u00f3mo se administra Ultomiris a pacientes con miastenia gravis?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#What_Are_the_Recommended_Doses_of_Ultomiris_for_Myasthenia_Gravis_Patients\" >\u00bfCu\u00e1les son las dosis recomendadas de Ultomiris para pacientes con miastenia gravis?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#What_Are_the_Possible_Side_Effects_of_Ultomiris_in_gMG_Patients\" >\u00bfCu\u00e1les son los posibles efectos secundarios de Ultomiris en pacientes con gMG?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#Who_Should_Not_Take_Ultomiris\" >\u00bfQui\u00e9n no debe tomar Ultomiris?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#What_Precautions_Should_You_Follow_Before_Taking_Ultomiris_Infusions\" >\u00bfQu\u00e9 precauciones debes seguir antes de tomar infusiones de Ultomiris?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#Conclusion\" >Conclusi\u00f3n<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_Ultomiris\"><\/span>\u00bfQu\u00e9 es Ultomiris?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Ultomiris es un medicamento aprobado por la FDA indicado para el tratamiento de la miastenia gravis generalizada (gMG) en pacientes adultos con anticuerpos antirreceptor de acetilcolina (Anti-AChR) positivos.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Los resultados positivos de la prueba de anticuerpos anti-receptor de acetilcolina (Anti-AChR) indican la presencia de estos autoanticuerpos, que contribuyen al desarrollo de la miastenia gravis.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Ultomiris tambi\u00e9n se conoce por el nombre del componente (o sustancia activa) que contiene, llamado ravulizumab, y solo est\u00e1 disponible para pacientes que est\u00e9n registrados en el <a href=\"https:\/\/ultomirisrems.com\/\">Ultomiris Programa REMS (Estrategia de Evaluaci\u00f3n y Mitigaci\u00f3n de Riesgos)<\/a>.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Happens_in_Generalized_Myasthenia_Gravis\"><\/span>\u00bfQu\u00e9 ocurre en la miastenia grave generalizada?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Normalmente, cuando una persona sana quiere mover o levantar algo, su cerebro env\u00eda se\u00f1ales a los m\u00fasculos a trav\u00e9s de los nervios. Estos nervios liberan acetilcolina (una sustancia qu\u00edmica), que se une a su receptor en la c\u00e9lula muscular esquel\u00e9tica y provoca la contracci\u00f3n muscular.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Sin embargo, en las personas con gMG, su sistema inmunol\u00f3gico produce autoanticuerpos, com\u00fanmente anticuerpos anti-receptor de acetilcolina (Anti-AChR) que atacan y bloquean el receptor de acetilcolina (AChR) e impiden que el m\u00fasculo se contraiga.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">La uni\u00f3n del anti-AChR (autoanticuerpo) a su objetivo desencadena la activaci\u00f3n de la <a href=\"https:\/\/my.clevelandclinic.org\/health\/body\/23370-complement-system\">sistema del complemento<\/a>, que consiste en el grupo de prote\u00ednas inmunes que normalmente est\u00e1n presentes en la sangre en un estado inactivo.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Cuando el sistema del complemento se activa, ataca y da\u00f1a las c\u00e9lulas musculares sanas e interrumpe la transmisi\u00f3n de se\u00f1ales nerviosas, lo que produce s\u00edntomas de gMG como debilidad muscular y fatiga.<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">La uni\u00f3n del anti-AChR (autoanticuerpo) a su objetivo desencadena la activaci\u00f3n de la <a href=\"https:\/\/my.clevelandclinic.org\/health\/body\/23370-complement-system\">sistema del complemento<\/a>, que consiste en el grupo de prote\u00ednas inmunes que normalmente est\u00e1n presentes en la sangre en un estado inactivo.&nbsp;<\/span><br><span style=\"font-weight: 400;\">Cuando el sistema del complemento se activa, ataca y da\u00f1a las c\u00e9lulas musculares sanas e interrumpe la transmisi\u00f3n de se\u00f1ales nerviosas, lo que produce s\u00edntomas de gMG como debilidad muscular y fatiga.<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Does_Ultomiris_Work\"><\/span>\u00bfC\u00f3mo funciona Ultomiris?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Ultomiris contiene un componente activo, \u201cravulizumab\u201d, que es un anticuerpo monoclonal dise\u00f1ado espec\u00edficamente para unirse e inhibir la activaci\u00f3n del sistema del complemento.&nbsp;<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ultomiris_Mode_of_Action\"><\/span>Modo de acci\u00f3n del Ultomiris<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Ravulizumab, principio activo de Ultomiris, bloquea una prote\u00edna clave (prote\u00edna C5) del sistema del complemento. Esta prote\u00edna clave activa otras prote\u00ednas del complemento y da\u00f1a las c\u00e9lulas musculares en la gMG. Al inhibir la prote\u00edna C5, Ultomiris bloquea la activaci\u00f3n del sistema del complemento y previene el da\u00f1o muscular en la gMG.&nbsp;<\/span><br>&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Is_Ultomiris_Administered_to_Myasthenia_Gravis_Patients\"><\/span>\u00bfC\u00f3mo se administra Ultomiris a pacientes con miastenia gravis?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Ultomiris se presenta en un vial monodosis que se administra por v\u00eda intravenosa mediante infusi\u00f3n intravenosa, comenzando con una dosis de carga. Tras esta dosis, se administra la primera dosis de mantenimiento 2 semanas despu\u00e9s, y las dosis subsiguientes se administran cada 8 semanas.&nbsp;<\/span><br>&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Are_the_Recommended_Doses_of_Ultomiris_for_Myasthenia_Gravis_Patients\"><\/span>\u00bfCu\u00e1les son las dosis recomendadas de Ultomiris para pacientes con miastenia gravis?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">La dosis de Ultomiris se ajusta seg\u00fan el peso corporal (kg) del paciente y el estado de la enfermedad. Seg\u00fan la gu\u00eda de dosificaci\u00f3n de la FDA, las dosis habituales de Ultomiris para adultos con gMG son las siguientes:<\/span><br><b>Para pacientes que pesan entre 40 kg y menos de 60 kg:<\/b><br><span style=\"font-weight: 400;\">La dosis de carga es de 2.400 mg, seguida de la dosis de mantenimiento de 3.000 mg cada 8 semanas.&nbsp;<\/span><br><b>Para pacientes que pesan entre 60 kg y menos de 100 kg:<\/b><br><span style=\"font-weight: 400;\">La dosis de carga es de 2.700 mg, seguida de la dosis de mantenimiento de 3.300 mg cada 8 semanas.&nbsp;<\/span><br><b>Para pacientes que pesan 100 kg o m\u00e1s:<\/b><br><span style=\"font-weight: 400;\">La dosis de carga es de 3.000 mg, seguida de la dosis de mantenimiento de 3.600 mg cada 8 semanas.<\/span><br><span style=\"font-weight: 400;\">&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Are_the_Possible_Side_Effects_of_Ultomiris_in_gMG_Patients\"><\/span>\u00bfCu\u00e1les son los posibles efectos secundarios de Ultomiris en pacientes con gMG?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright\"><img decoding=\"async\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/man-coughing.jpg\" alt=\"Man with upper respiratory tract infection coughing\" class=\"wp-image-23933\"\/><\/figure>\n<\/div>\n\n\n<p><span style=\"font-weight: 400;\">Los efectos secundarios m\u00e1s comunes de Ultomiris informados por pacientes adultos con miastenia generalizada son diarrea e infecci\u00f3n del tracto respiratorio superior.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Ultomiris tambi\u00e9n incluye una advertencia sobre infecciones meningoc\u00f3cicas graves y sepsis, que pueden ser mortales si no se diagnostican y tratan a tiempo. Por lo tanto, se recomienda que los pacientes reciban una vacuna para protegerse contra las infecciones meningoc\u00f3cicas al menos dos semanas antes de comenzar el tratamiento de infusi\u00f3n de Ultomiris.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Who_Should_Not_Take_Ultomiris\"><\/span>\u00bfQui\u00e9n no debe tomar Ultomiris?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Cualquier persona con una infecci\u00f3n activa por Neisseria meningitidis (la bacteria que causa <a href=\"https:\/\/www.cdc.gov\/meningococcal\/index.html\">enfermedad meningoc\u00f3cica<\/a>\u2014no debe utilizar Ultomiris.<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Adem\u00e1s, los pacientes que no hayan recibido la vacuna contra Neisseria meningitidis no deben recibir la terapia a menos que posponer el tratamiento resulte en un mayor riesgo de infecci\u00f3n meningoc\u00f3cica.<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Precautions_Should_You_Follow_Before_Taking_Ultomiris_Infusions\"><\/span>\u00bfQu\u00e9 precauciones debes seguir antes de tomar infusiones de Ultomiris?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Consulte a su proveedor de atenci\u00f3n m\u00e9dica en los siguientes casos antes de iniciar las infusiones de Ultomiris:&nbsp;<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">Si tienes una <\/span><b>fiebre o infecci\u00f3n<\/b><span style=\"font-weight: 400;\">, no debe recibir Ultomiris porque puede empeorar su condici\u00f3n.<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Si tu estas <\/span><b>embarazada <\/b><span style=\"font-weight: 400;\">o<\/span><b> tiene intenci\u00f3n de quedar embarazada, <\/b><span style=\"font-weight: 400;\">No deber\u00edas recibir Ultomiris<\/span><b>, <\/b>s<span style=\"font-weight: 400;\">Ya que a\u00fan se desconoce el efecto de este f\u00e1rmaco en los fetos.&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Si tu estas <\/span><b>amamantando o planea amamantar<\/b><span style=\"font-weight: 400;\">, No debe recibir Ultomiris. Dado que se desconoce si el Ultomiris pasa a la leche materna, se recomienda NO amamantar durante el tratamiento y durante al menos 8 meses despu\u00e9s del mismo.<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Si es al\u00e9rgico a cualquier componente de Ultomiris, no debe recibir infusiones de Ultomiris.&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Si tomas <\/span><b>multivitaminas, suplementos herbales o medicamentos de venta libre, <\/b><span style=\"font-weight: 400;\">Consulte a su proveedor de atenci\u00f3n m\u00e9dica para ajustar la dosis.&nbsp;<\/span><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusi\u00f3n<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">En resumen, Ultomiris (ravulizumab) es un medicamento intravenoso para el tratamiento de los s\u00edntomas de la miastenia gravis generalizada. Este f\u00e1rmaco inhibe la prote\u00edna C5, clave en el sistema del complemento, una parte del sistema inmunitario que altera la transmisi\u00f3n de se\u00f1ales nerviosas y causa gMG.&nbsp;&nbsp;<\/span><br>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Si le diagnostican miastenia gravis generalizada (MGg), su m\u00e9dico podr\u00eda recetarle Ultomiris. Ultomiris es un medicamento aprobado por la FDA indicado para el tratamiento de la miastenia gravis generalizada (MGg) en pacientes adultos con anticuerpos contra el receptor de acetilcolina (anti-AChR) positivos.<\/p>","protected":false},"author":13,"featured_media":25909,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[64],"tags":[17],"class_list":["post-23931","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-discontinued","tag-dr-saba-rassouli"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ultomiris: A Treatment for Generalized Myasthenia Gravis<\/title>\n<meta name=\"description\" content=\"This article discusses Ultomiris and how it can help those with myasthenia gravis. Topics include mode of action, dosage, and side effects.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ultomiris: A Treatment for Generalized Myasthenia Gravis\" \/>\n<meta property=\"og:description\" content=\"This article discusses Ultomiris and how it can help those with myasthenia gravis. Topics include mode of action, dosage, and side effects.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-05T20:38:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-19T21:58:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Saba Rassouli, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Saba Rassouli, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/\"},\"author\":{\"name\":\"Dr. Saba Rassouli, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/f70b3467e035aab4ae14bdadd64c5c01\"},\"headline\":\"Ultomiris: A Treatment for Generalized Myasthenia Gravis\",\"datePublished\":\"2024-03-05T20:38:14+00:00\",\"dateModified\":\"2026-03-19T21:58:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/\"},\"wordCount\":881,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/myasthenia-gravis-patient.jpg\",\"keywords\":[\"Dr. Saba Rassouli\"],\"articleSection\":[\"Discontinued\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/\",\"name\":\"Ultomiris: A Treatment for Generalized Myasthenia Gravis\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/myasthenia-gravis-patient.jpg\",\"datePublished\":\"2024-03-05T20:38:14+00:00\",\"dateModified\":\"2026-03-19T21:58:09+00:00\",\"description\":\"This article discusses Ultomiris and how it can help those with myasthenia gravis. Topics include mode of action, dosage, and side effects.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/myasthenia-gravis-patient.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/myasthenia-gravis-patient.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Ultomiris patient stretching numb arm\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/discontinued\\\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ultomiris: A Treatment for Generalized Myasthenia Gravis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/f70b3467e035aab4ae14bdadd64c5c01\",\"name\":\"Dr. Saba Rassouli, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g\",\"caption\":\"Dr. Saba Rassouli, PharmD\"},\"description\":\"Dr. Saba Rassouli, PharmD was born and raised in Iran. She received her pharmacy degree from Marshall B. Ketchum University in 2022, where she graduated cum laude. The most rewarding part of her job is having the opportunity to care for each patient as if they were family and hearing about how happy and satisfied they are with the services provided by AmeriPharma. In her free time, she likes to go on walks, read books, and try different restaurants and foods.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/saba-rassouli\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ultomiris: Un tratamiento para la miastenia grave generalizada","description":"Este art\u00edculo analiza el Ultomiris y c\u00f3mo puede ayudar a las personas con miastenia gravis. Entre los temas tratados se incluyen su mecanismo de acci\u00f3n, la dosis y los efectos secundarios.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/","og_locale":"es_MX","og_type":"article","og_title":"Ultomiris: A Treatment for Generalized Myasthenia Gravis","og_description":"This article discusses Ultomiris and how it can help those with myasthenia gravis. Topics include mode of action, dosage, and side effects.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2024-03-05T20:38:14+00:00","article_modified_time":"2026-03-19T21:58:09+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg","type":"image\/jpeg"}],"author":"Dr. Saba Rassouli, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Saba Rassouli, PharmD","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/"},"author":{"name":"Dr. Saba Rassouli, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/f70b3467e035aab4ae14bdadd64c5c01"},"headline":"Ultomiris: A Treatment for Generalized Myasthenia Gravis","datePublished":"2024-03-05T20:38:14+00:00","dateModified":"2026-03-19T21:58:09+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/"},"wordCount":881,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg","keywords":["Dr. Saba Rassouli"],"articleSection":["Discontinued"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/","url":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/","name":"Ultomiris: Un tratamiento para la miastenia grave generalizada","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg","datePublished":"2024-03-05T20:38:14+00:00","dateModified":"2026-03-19T21:58:09+00:00","description":"Este art\u00edculo analiza el Ultomiris y c\u00f3mo puede ayudar a las personas con miastenia gravis. Entre los temas tratados se incluyen su mecanismo de acci\u00f3n, la dosis y los efectos secundarios.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg","width":1280,"height":853,"caption":"Ultomiris patient stretching numb arm"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/ultomiris-a-treatment-for-generalized-myasthenia-gravis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"Ultomiris: A Treatment for Generalized Myasthenia Gravis"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/f70b3467e035aab4ae14bdadd64c5c01","name":"Dra. Saba Rassouli, Farmac\u00e9utica","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a5087340dca0d3046e3ff88f5dfa11d515d21ea9e06e6aec23e56d7fddfee7ce?s=96&d=mm&r=g","caption":"Dr. Saba Rassouli, PharmD"},"description":"La Dra. Saba Rassouli, doctora en farmacia, naci\u00f3 y creci\u00f3 en Ir\u00e1n. Obtuvo su t\u00edtulo en farmacia en la Universidad Marshall B. Ketchum en 2022, donde se gradu\u00f3 con honores. Lo m\u00e1s gratificante de su trabajo es tener la oportunidad de atender a cada paciente como si fuera de su familia y escuchar lo contentos y satisfechos que est\u00e1n con los servicios de AmeriPharma. En su tiempo libre, le gusta pasear, leer y probar diferentes restaurantes y comidas.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/saba-rassouli\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Saba Rassouli, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/saba-rassouli\/"},"uagb_comment_info":0,"uagb_excerpt":"If you are diagnosed with generalized myasthenia gravis (gMG), your healthcare provider might prescribe Ultomiris.\u00a0Ultomiris is an FDA-approved medication indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (Anti-AChR) antibody positive.","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/03\/myasthenia-gravis-patient.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Saba Rassouli, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/saba-rassouli\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/discontinued\/\" rel=\"category tag\">Discontinued<\/a>","rttpg_excerpt":"If you are diagnosed with generalized myasthenia gravis (gMG), your healthcare provider might prescribe Ultomiris.\u00a0Ultomiris is an FDA-approved medication indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (Anti-AChR) antibody positive.","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/23931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=23931"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/23931\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/25909"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=23931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=23931"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=23931"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}